$19.66
0[0.00%]
Last update: 4:00PM Get Real Time Here
AnaptysBio
(NASDAQ:ANAB)AnaptysBio Stock (NASDAQ:ANAB), Analyst Ratings, Price Targets, Predictions
AnaptysBio Inc has a consensus price target of $37.79, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Leerink Partners, Wells Fargo, and JP Morgan on April 16, 2024, April 11, 2024, and April 1, 2024. With an average price target of $43.67 between Leerink Partners, Wells Fargo, and JP Morgan, there's an implied 122.11% upside for AnaptysBio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Wells Fargo
JP Morgan
Wedbush
BTIG
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for AnaptysBio
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | ANAB | Buy Now | AnaptysBio | $19.66 | 139.06% | Leerink Partners | David Risinger | → $47 | Initiates | → Outperform | Get Alert |
| 04/11/2024 | ANAB | Buy Now | AnaptysBio | $19.66 | 184.84% | Wells Fargo | Derek Archila | → $56 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | ANAB | Buy Now | AnaptysBio | $19.66 | 42.42% | JP Morgan | Anupam Rama | $30 → $28 | Maintains | Neutral | Get Alert |
| 03/12/2024 | ANAB | Buy Now | AnaptysBio | $19.66 | — | Wedbush | David Nierengarten | $20 → $34 | Upgrade | Neutral → Outperform | Get Alert |
| 02/26/2024 | ANAB | Buy Now | AnaptysBio | $19.66 | 179.76% | BTIG | Julian Harrison | → $55 | Initiates | → Buy | Get Alert |
| 02/21/2024 | ANAB | Buy Now | AnaptysBio | $19.66 | 154.32% | Stifel | Alex Schwartz | → $50 | Initiates | → Buy | Get Alert |
| 02/16/2024 | ANAB | Buy Now | AnaptysBio | $19.66 | 306.92% | Piper Sandler | Yasmeen Rahimi | → $80 | Initiates | → Overweight | Get Alert |
| 11/29/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 1.73% | Wedbush | David Nierengarten | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 11/03/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 1.73% | Wedbush | David Nierengarten | $18 → $20 | Maintains | Neutral | Get Alert |
| 11/02/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 6.82% | UBS | Eliana Merle | $28 → $21 | Maintains | Neutral | Get Alert |
| 08/08/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 32.25% | Wedbush | David Nierengarten | $29 → $26 | Maintains | Neutral | Get Alert |
| 05/22/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 52.59% | JP Morgan | Anupam Rama | $31 → $30 | Upgrade | Underweight → Neutral | Get Alert |
| 05/12/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 47.51% | Wedbush | David Nierengarten | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 128.89% | Guggenheim | Yatin Suneja | $44 → $45 | Maintains | Buy | Get Alert |
| 04/12/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | 57.68% | JP Morgan | Anupam Rama | $32 → $31 | Maintains | Underweight | Get Alert |
| 01/06/2023 | ANAB | Buy Now | AnaptysBio | $19.66 | — | Raymond James | Timur Ivannikov | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/18/2022 | ANAB | Buy Now | AnaptysBio | $19.66 | 62.77% | JP Morgan | Anupam Rama | $24 → $32 | Maintains | Underweight | Get Alert |
| 11/09/2022 | ANAB | Buy Now | AnaptysBio | $19.66 | 93.29% | Raymond James | Steven Seedhouse | $30 → $38 | Maintains | Outperform | Get Alert |
| 11/01/2022 | ANAB | Buy Now | AnaptysBio | $19.66 | — | Guggenheim | Yatin Suneja | — | Upgrade | Neutral → Buy | Get Alert |
FAQ
What is the target price for AnaptysBio (ANAB)?
The latest price target for AnaptysBio (NASDAQ: ANAB) was reported by Leerink Partners on April 16, 2024. The analyst firm set a price target for $47.00 expecting ANAB to rise to within 12 months (a possible 139.06% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AnaptysBio (ANAB)?
The latest analyst rating for AnaptysBio (NASDAQ: ANAB) was provided by Leerink Partners, and AnaptysBio initiated their outperform rating.
When was the last upgrade for AnaptysBio (ANAB)?
The last upgrade for AnaptysBio Inc happened on March 12, 2024 when Wedbush raised their price target to N/A. Wedbush previously had a neutral for AnaptysBio Inc.
When was the last downgrade for AnaptysBio (ANAB)?
The last downgrade for AnaptysBio Inc happened on January 6, 2023 when Raymond James changed their price target from N/A to N/A for AnaptysBio Inc.
When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating AnaptysBio (ANAB) correct?
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a initiated with a price target of $0.00 to $47.00. The current price AnaptysBio (ANAB) is trading at is $19.66, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.